We subscribe to the HONcode principles of the Health On the Net Foundation. Because in some studies if one inherits a BRCA1 mutation that puts one at an 85 percent lifetime risk for developing breast cancer. And now I think it's fairly still controversial about whether actually tamoxifen benefits that group. And the reason I say that is because at the same time the American tamoxifen trial was done, a British trial was done, and the British trial was negative. But one of the underlying concerns is that the British trial might have enrolled more women with familial breast cancer.
Nobody knows yet, what the patient population was, so that's a very active question.
There's a very big overview of the prevention trials. That will change, this is one of the moving targets. Once everybody gets their tumor sequence we'll know the answer to that. But for right now it's unknown.